Home > Boards > US Listed > Cannabis >

Zynerba Pharmaceuticals (ZYNE)

ZYNE RSS Feed
Add ZYNE Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 11/16/2020 12:16:12 PM - Followers: 105 - Board type: Free - Posts Today: 0


Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing synthetic cannabinoid therapeutics formulated for transdermal delivery. The Company is evaluating approximately two product candidates, ZYN002 and ZYN001, in over five indications. The Company intends to study ZYN002 in patients with refractory epilepsy, osteoarthritis and Fragile X syndrome. The Company's ZYN002 is synthetic cannabidiol (CBD) formulated as a permeation-enhanced gel for transdermal delivery. ZYN002 is being developed as a clear that is designed to provide controlled drug delivery with once- or twice-daily dosing. ZYN001 is a pro-drug of tetrahydrocannabinol (THC) that enables transdermal delivery through a patch. The Company intends to test the ZYN001 patch for application to the arm, back and thigh. The Company intends to study ZYN001 in patients with fibromyalgia and peripheral neuropathic pain.

Investor Relations

Corporate Profile

Zynerba (NASDAQ: ZYNE) is pioneering the development of patent-protected, next-generation synthetic cannabinoid therapeutics formulated for transdermal delivery. Its two lead product candidates in development include ZYN002 and ZYN001, which are being evaluated in five indications. ZYN002 is the first and only synthetic cannabidiol (CBD) formulated as a permeation-enhanced gel for transdermal delivery. In June 2016, the company initiated the STAR 1 Phase 2 clinical trial in refractory epilepsy patients and in August 2016, initiated the STOP Phase 2 clinical trial in patients with osteoarthritis of the knee. A Phase 2 clinical trial in patients with Fragile X syndrome will be initiated in the second half of 2016. 

ZYN001, a prodrug of THC that enables transdermal delivery through the skin and circulatory system via a patch, is in preclinical development. A Phase 1 clinical trial is planned in the first half of 2017.

In August 2015, Zynerba completed an initial public offering, raising net proceeds of $42.1 million. As of June 30, 2016, cash and cash equivalents totaled $32.1 million, which is projected to fund five Phase 2 clinical trials through 2017.





Zynerba Pharmaceuticals, Inc., (Nasdaq: ZYNE) announced today the pricing of its initial public offering of 3 million shares of common stock at a public offering price of $14.00 per share, before underwriting discounts. All of the shares in the offering are being sold by Zynerba. In addition, Zynerba has granted the underwriters an option to purchase up to 450,000 additional shares of common stock at the public offering price, less the underwriting discount. Zynerba's common stock has been approved for listing on the NASDAQ Global Market and is expected to begin trading under the symbol "ZYNE" on August 5, 2015.

Jefferies LLC and Piper Jaffray & Co. are acting as joint book-running managers for the offering, and Canaccord Genuity Inc. and Oppenheimer & Co. Inc. are acting as co-managers for the offering. This offering is being made only by means of a prospectus.



Extremely low float:

Fundamentals

A table providing the fundamentals of the stock
EPS (TTM) 9/30/2016 | -2.47
P/E Ratio 9/30/2016 | --
Market Cap Micro Cap | 146M
Shares Outstanding 9.95M
Float 7.2M

 

ZYNE
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ZYNE News: Zynerba Pharmaceuticals Announces the Acceptance of Two Posters at the 2020 Virtual Annual Meeting of the American Epilepsy S... 11/23/2020 11:45:00 AM
ZYNE News: Current Report Filing (8-k) 11/09/2020 07:17:39 AM
ZYNE News: Zynerba Pharmaceuticals Reports Third Quarter 2020 Financial Results and Operational Highlights 11/09/2020 06:45:00 AM
ZYNE News: Current Report Filing (8-k) 10/15/2020 04:16:27 PM
ZYNE News: Zynerba Pharmaceuticals Presents Data Supporting FMR1 Methylation Status as a Correlate to Fragile X Syndrome Severity at the... 10/15/2020 03:06:10 PM
PostSubject
#2628   http://ir.zynerba.com/sec-filings/sec-filing/sc-13ga/0001213900-20-037198 steadykickin 11/16/20 12:16:12 PM
#2627   LOL.. dhbuzz 11/12/20 07:46:50 PM
#2626   $zyne $3.78 ? 0.0 (0.00%) Taurus69 11/12/20 05:14:51 AM
#2625   Nice move in Germany Friday for ZYNE ON dhbuzz 11/07/20 10:17:29 AM
#2624   I continue to hold, positive news on FMFX dhbuzz 11/07/20 09:48:27 AM
#2623   Still here. Still a great price to load up Jdanger 2 11/06/20 02:53:09 PM
#2622   . dhbuzz 11/06/20 01:39:19 AM
#2621   $zyne $3.4 v -0.03 (-0.87%) Taurus69 10/31/20 02:44:17 PM
#2620   I would think there should be word from Stockfun1 10/29/20 08:34:01 AM
#2619   We wait,and we watch. dhbuzz 10/28/20 10:59:27 PM
#2618   https://www.tipranks.com/stocks/zyne/forecast dhbuzz 10/27/20 10:58:37 AM
#2617   https://finance.yahoo.com/news/canaccord-predicts-over-100-rally-150126313.html dhbuzz 10/27/20 10:49:38 AM
#2616   Short interest only 19.9%. Anyone understand what’s going Stockfun1 10/20/20 11:30:50 AM
#2615   . dhbuzz 10/17/20 03:07:31 AM
#2614   NEWS: $ZYNE Zynerba Pharmaceuticals Presents Data Supporting FMR1 whytestocks 10/15/20 08:15:31 PM
#2613   JUST IN: $ZYNE New Data Describing Statistically Significant whytestocks 10/15/20 03:30:26 PM
#2612   Amazing results resented at the conference today. ZYNE Jdanger 2 10/15/20 03:13:01 PM
#2611   dhbuzz 10/08/20 06:07:42 AM
#2610   $zyne $3.41 ^ 0.04 (1.19%) Taurus69 10/06/20 11:12:37 PM
#2609   “Zynerba is committed to developing Zygel™ CBD gel dhbuzz 09/19/20 12:19:26 PM
#2608   https://byebyedoctor.com/digeorge-syndrome/ dhbuzz 09/19/20 11:59:42 AM
#2607   ZANERBA is about to get some serious dhbuzz 09/19/20 11:46:07 AM
#2606   Hey Lumpy dhbuzz 09/18/20 09:01:34 AM
#2605   https://seekingalpha.com/article/4375033-making-case-for-zynerba-pharmaceuticals Stockfun1 09/18/20 08:29:49 AM
#2604   Today may get interesting. dhbuzz 09/18/20 07:46:01 AM
#2603   https://seekingalpha.com/article/4375033-making-case-for-zynerba-pharmaceuticals dhbuzz 09/18/20 07:16:57 AM
#2602   NEWS: $ZYNE Zynerba Pharmaceuticals Receives Orphan Drug Designation whytestocks 09/17/20 11:45:13 PM
#2601   Love the market response. It’s really about time. Stockfun1 09/17/20 04:39:20 PM
#2600   Zynerba Pharmaceuticals Receives Orphan Drug Designation for Cannabidiol dhbuzz 09/17/20 02:37:19 PM
#2599   Stockfun Check out MTNB dhbuzz 09/15/20 11:34:25 AM
#2598   I think your right!! Stockfun1 09/15/20 11:03:58 AM
#2597   Just a reminder...The next FMFX response from FDA dhbuzz 09/15/20 10:58:07 AM
#2596   As I said ... (one step ahead) dhbuzz 09/15/20 10:41:58 AM
#2595   The meeting with the FDA will be an dhbuzz 09/15/20 10:25:37 AM
#2594   Stockfun,maybe we get a little feed back on dhbuzz 09/15/20 09:59:32 AM
#2593   Agreed dhbuzz. Very much agreed. Stockfun1 09/15/20 09:41:41 AM
#2592   Concerning yesterdays updates. dhbuzz 09/15/20 09:28:08 AM
#2591   Maybe something like this in Zanerbas future one day? dhbuzz 09/14/20 09:38:13 AM
#2590   Here's to a great week ahead! dhbuzz 09/14/20 09:31:27 AM
#2589   I'm sure it will be recorded Stockfun. dhbuzz 09/14/20 08:07:53 AM
#2588   Lol!! Enticing me to buy now aren’t you??? Stockfun1 09/13/20 11:34:06 PM
#2587   Wouldn't it be a nice Mon. if FDA dhbuzz 09/13/20 10:42:24 PM
#2586   NSS dhbuzz 09/13/20 10:03:25 PM
#2585   $zyne $3.55 ^ 0.04 (1.14%) Taurus69 09/13/20 02:38:14 PM
#2584   I think its better than 50\50 simply dhbuzz 09/13/20 11:51:07 AM
#2583   Agree with you on the ASD. Also Stockfun1 09/13/20 11:25:19 AM
#2582   Trial results info on this are also in dhbuzz 09/13/20 10:42:35 AM
#2581   If FDA does not give NDA ok with dhbuzz 09/13/20 10:18:35 AM
#2580   We are certainly in buying territory now. Stockfun1 09/12/20 09:59:43 PM
#2579   dhbuzz 09/12/20 09:32:49 PM
PostSubject
Consent Preferences